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Abstract
Plasmodium falciparum, the most devastating human malaria parasite, confers 
higher morbidity and mortality. Although efforts have been made to develop an 
effective malaria vaccine, stage- and species-specific short-lived immunity crippled 
these efforts. Hence, antimalarial drug treatment becomes a mainstay for the treat-
ment of malaria infection in the wake of the unavailability of an effective vaccine. 
Further, there has been a wide array of antimalarial drugs effective against various 
developmental stages of P. falciparum due to their different structures, modes of 
action, and pharmacodynamics as well as pharmacokinetics. The development 
of resistance against almost all frontline drugs by P. falciparum indicates the need 
for combination therapy (artemisinin-based combination therapy; ACT) to treat 
patients with P. falciparum. A higher pool of parasitemia under discontinuous in 
vivo artemisinin drug pressure in a developed humanized mouse allows the selec-
tion of artesunate resistant (ART-R) P. falciparum. Intravenously administered 
artesunate, using either single flash doses or a 2-day regimen, to the P. falciparum-
infected human blood chimeric NOD/SCID.IL-2Rγ−/− immunocompromised (NSG) 
mice, with progressive dose increments upon parasite recovery, was the strategy 
deployed to select resistant parasites. Parasite susceptibility to artemisinins and 
other antimalarial compounds was characterized in vitro and in vivo. P. falciparum 
has shown to evolve extreme artemisinin resistance as well as co-resistance to 
antimalarial drugs. Overall, the present information shall be very useful in devising 
newer therapeutic strategies to treat human malaria infection.




Malaria is a leading parasitic disease caused by protozoans belonging to the 
genus Plasmodium (P.) when injected by the female mosquito (Anopheles) in 
humans during a blood meal. Out of 172 species of Plasmodium parasite, only five 
species are reportedly known to cause malaria infection: Plasmodium falciparum, 
Plasmodium malariae, Plasmodium vivex, Plasmodium ovale, and Plasmodium 
knowlesi. The parasite completes its sexual and asexual cycles in a very complicated 
manner [1]. Plasmodium gametocytes are taken up during the blood meal from the 
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human host and travel through salivary glands to the gut of Anopheles and continue 
the sexual multiplication. The haploid male and female gametes fertilize and give 
rise to zygote in the gut, which further grows and elongates into the ookinetes. 
Ookinetes following several replication processes become oocyst that transforms 
into sporozoites [2]. These sporozoites move from the gut to salivary glands and are 
released by the mosquitoes into the human bloodstream during a blood meal.
Once sporozoites are released in the bloodstream, the asexual development 
stage gets started [3]. Sporozoites traverse to their first incubation site, that is, 
hepatocytes (pre-erythrocytic stage), and later continues the asexual blood-stage 
infection inside red blood cells (RBCs). The asexual blood-stage infection results in 
clinical manifestations of the disease. Some sporozoites reach the liver within a few 
hours and penetrate the hepatocyte and undergo asexual replication known as exo-
erythrocytic schizogony. Each sporozoite develops into a schizont containing 18–26 
merozoites. The entire pre-erythrocytic phase lasts about 5–16 days depending upon 
the parasite species. RBCs are “center stage” and host the asexual development of 
Plasmodium. The merozoites (infective form) released from the liver recognize, 
attach, and enter the RBCs quickly. Merozoite passes through a developmental 
transformation beginning with a characteristic ring stage and leading to the forma-
tion of a multinucleated schizont within RBCs. Mature schizont ruptures to release 
the merozoites and continues the multiplication in RBCs. Each mature schizont con-
tains around 18–26 merozoites, and these are released following the lysis of RBC to 
invade fresh RBCs. It is the lysis of RBCs that induces the bouts of fever and anemia 
in the infected individual, whereas, in P. vivax and P. ovale infection, a few merozo-
ites remain in dormant stages for four months or year causing malaria relapse [4].
1.2 Malaria vaccine
Globally, malaria is one of the leading causes of mortality (0.3–2.3%), and Africa 
and Asia are highly endemic regions among the other continents [5]. According 
to World Health Organization, approximately 299 million cases of malaria and 
400,000 deaths have been reported worldwide in 2019 [6]. A variety of antimalarial 
drugs are available but the emergence of resistance has been a major setback in 
containing malaria infection. Currently, Mosquirix (RTS,S/AS01) developed by 
GlaxoSmithKline is the only vaccine available in the market against malaria. RTS,S/
AS01 is an engineered vaccine comprising of the genes from the outer protein of 
P. falciparum circumsporozoites and a portion of a hepatitis B surface antigen with 
chemical adjuvant to boost the immune responses. Mosquirix reduced malaria cases 
in children to nearly half [7] and has had 40% efficacy in children receiving four 
vaccine doses [8]. However, the efficacy dropped to 26% in children receiving only 
three vaccine doses and 33% efficacy was observed during the first year in infants 
(up to 3 months old). Further, the effectiveness of Mosquirix is only for one year and 
failed to provide long-term protection but could be combined with chemotherapy to 
prevent the transmission of malaria in low-endemic regions [9].
A variety of vaccines focusing on irradiated sporozoites is under trial, which 
may give exposure to the array of antigens and help induce protective immunity 
against malaria [1].
1.3 Drug-based therapy
Antimalarial drugs are the most commonly used treatment option for malaria in 
tropical regions. Three types of antimalarial drugs are currently available viz. aryl 
amino alcohol compounds (quinine, lumefantrine, chloroquine, amodiaquine, meflo-
quine, etc.), antifolate compounds (pyrimethamine and sulfadoxine), and artemisinin 
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and derivatives [10]. Plasmodium parasites have a complex life cycle that involves a 
mammalian and an invertebrate host. All the symptoms are caused by the repeated 
rupture and penetration of erythrocytes by the asexual blood-stage parasites (mero-
zoites). Hence, most of the antimalarial drugs target the asexual erythrocytic stage 
of the parasite. As per WHO’s Model List of Essential Medicines (MLEM), currently, 
there are 14 curative drugs for the treatment of malaria (treatment postinfection) and 
6 prophylactic medicines (treatment before infection), either single or in combination 
[11]. Curative drugs for P. falciparum are mostly artemisinin-based combinations with 
artemisinin derivative (short half-life) in combination with partner drug(s) with a 
different mechanism of action (longer half-life). Out of 14 curative drugs, chloroquine 
is used for P. vivax, primaquine is used for P. vivax and P. ovale both, and the rest 12 are 
used for treating P. falciparum malaria.
1.3.1 Quinine
First isolated from the bark of the cinchona tree in 1820, and it remained one of 
the most effective malaria treatment options till the early 2000s [12]. Even today, 
quinine is obtained entirely from its natural source due to its difficult synthesis of 
the active molecule. Resistance for quinine was first reported in the 1980s, and since 
2006, not being used as a frontline antimalarial drug [12]. However, the drug is still 
present on the WHO’s list of essential medicines and is used wherever artemisinins 
are not available [11]. Quinine has blood schizonticidal and gametocytocidal activ-
ity against P. vivax and P. malariae. Quinine also inhibits heme polymerase activity 
(required to convert toxic heme into nontoxic hemazoin) and, hence, leads to the 
accumulation of heme (cytotoxic substrate) in parasites.
1.3.2 Chloroquine
It was used to treat all forms of malaria infections with fewer side effects in the 
1940s [13]. Blood stage of P. vivax, P. ovale, and P. malariae, sensitive strains of  
P. falciparum, and gametocytes of P. vivax are sensitive to chloroquine. It is highly 
effective in controlling acute malaria infection as compared to quinine. Moreover, 
it has been efficient and safer to use to treat sensitive cases. The first resistance case 
was reported in the 1950s and by the time, many malaria parasites have developed 
resistance against chloroquine. As per MLEM, chloroquine is used as a curative and 
prophylactic drug against P. vivax in the regions where resistance is not known to 
evolve (Central American regions) [11].
1.3.3 Amodiaquine
It was first synthesized in 1948 [14] and used in combination with artesunate for 
treating uncomplicated P. falciparum malaria (Camoquine® or Coarsucam™) [15]. 
The mechanism of action of amodiaquine is similar to that of chloroquine involving 
inhibition of hemozoin formation [16].
1.3.4 Pyrimethamine and sulfadoxine
In the early 1950s, Elion G and Hitchings G developed pyrimethamine [17] 
and Elion, Hitchings, and Black won the joint Nobel Prize in Physiology or 
Medicine (1988) for “their discoveries of important principles for drug treatment.” 
Sulfadoxine was developed in the early 1960s [18] and in 1981, the pyrimethamine 
and sulfadoxine combination was approved for the treatment of malaria. The 
emergence of high levels of resistance against the combination of pyrimethamine 
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and sulfadoxine led to its discontinuation as a prophylactic drug since both drugs 
inhibit the parasite’s folate biosynthesis pathway (dihydrofolate reductase, DHFR 
and dihydropteroate synthetase, respectively) [19].
1.3.5 Primaquine
Primaquine, an 8-aminoquinoline, was first used in early 1950s. 8-aminoquino-
lines eliminates mature P. falciparum gametocytes, exo-erythrocytic (hepatic) stage 
of all Plasmodium species, and prevents the relapse cases of P. vivax and P. ovale 
showing suboptimal blood-stage activity. Despite its remarkable antimalarial proper-
ties, primaquine is reportedly known to confer severe side effects [20].
1.3.6 Piperaquine
It was developed as a part of the Chinese National Malaria Elimination 
Programme in the 1960s [21]. Although China used this drug as a replacement 
for chloroquine, the emergence of resistance against piperaquine prohibited 
its use as monotherapy. Currently, this is used with a partner drug with DHA 
(Eurartesim®) as a combination therapy [22]. It binds to heme-containing spe-
cies by blocking heme detoxification and acts through getting accumulated in the 
digestive vacuole [14].
1.3.7 Doxycycline
In the early 1960s, Pfizer Inc. (USA) invented doxycyclin, a synthetically derived 
broad-spectrum bacteriostatic agent from Streptomyces sp. Doxycyclin is an effica-
cious prophylactic drug and, in combination with a partner drug, is highly effective 
as a curative drug for Plasmodium infection. Doxycycline is particularly used as a 
preventive drug in the regions with chloroquine and multidrug-resistant (MDR)  
P. falciparum malaria. It is not recommended for pregnant women and children 
below 8 years of age, but adverse effects were scarcely reported [23].
1.3.8 Mefloquine
American Army developed mefloquine in the 1970s [24] and is still part of the 
MLEM. Initially introduced for the treatment of chloroquine-resistant malaria, 
mefloquine has been used as a curative (in combination with artesunate) and pro-
phylactic drug. In the late 1980s, resistance cases were reported for mefloquine [25]. 
Further, antimalarial action is mediated by disrupting the hemoglobin digestion in 
the asexual erythrocytic stage of the parasite [14]. The rendered adverse effects on 
the central nervous system prohibited its use as an antimalarial drug [26].
1.3.9 Artemisinin and its derivatives
Tu Youyou first isolated artemisinin in 1971, from a traditional Chinese 
medicine plant Artemisia annua [27], and was conferred Nobel Prize (2015) in 
Physiology or Medicine for “her discoveries concerning a novel therapy against 
malaria.” Artemisinin and its derivatives (artemether, artesunate, and arteether) 
are metabolized to its active compound DHA and are effective against all MDR 
forms of P. falciparum. Artemisinins acts in multiple ways including the generation 
of free radicals after being activated by heme, which, in turn, destroys proteins 
essentially required for the parasite growth and development [28]. Additionally, 
its action is associated with upregulation of unfolded protein response (UPR) 
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pathways [29] and downregulation of P. falciparum phosphatidylinositol-3-kinase 
(PfPI3K) [30] and Ca2+ transporter (PfATP6) [31]. Artemisinins are crucial to 
fight the battle against malaria with artemisinin combination therapy (ACT) 
accounting for the majority of current antimalarial treatments [22], and in the late 
2000s, emerging artemisinin resistance was noticed in Southeast (SE) Asia [5, 32].
1.3.10 Lumefantrine
Chinese antimalarial research effort “Project 523” that led to the discovery of 
artemisinin also synthesized lumefantrine in 1976 [33]. Currently, lumefantrine is 
used in combination with artemether. Lumefantrine is known to inhibit the tran-
scriptional and translational pathway of malaria parasites [16].
2. Artemisinin resistance
One of the greatest challenges in achieving malaria control is antimalarial drug 
resistance (Figure 1). It has been associated with the malaria dissemination to new 
areas and resurgence in areas where the disease had been eliminated from. The 
situation is worsened by the incomplete treatments as it puts massive drug selection 
pressure on P. falciparum parasites, and hence, it helps evolve resistance against 
all frontline drugs. Chloroquine resistance leads to the resurgence and spread of 
malaria for decades in most countries in the 1960s [34]. Pyrimethamine, amo-
diaquine (chloroquine analog), arylaminoalcohols mefloquine, and halofantrine 
too suffered reduced efficacy in the 1980s, spreading resistant parasites. WHO 
recommended the combined use of two or more compounds with different modes 
of action to provide necessary cure rates and delay the development and spread 
of resistance. With low mixed-strain transmission rates, Southeast (SE) Asia was 
historically the first region to show resistance to frontline drugs [32]. Resistance to 
chloroquine, mefloquine, and sulfadoxine-pyrimethamine was initially seen in SE 
Asia [35, 36]. Artemisinin-based combination therapies (ACTs) have been seen as 
effective in controlling malaria. ACTs were a first-line treatment option for malaria 
since the early 2000s and were quickly adopted worldwide [34].
The mechanism of action of most antimalarials depends on targeting a single 
pathway/molecule, for example, DHFR-mediated folate synthesis (sulfadoxine-
pyrimethamine), cytochrome bc1 (atovaquone), and heme detoxification (chlo-
roquine). The artemisinin(s) binds to an array of parasite proteins and influences 
multiple cellular processes including glycolysis, translational pathway, and cell 
cycle regulation [37–40]. Some studies also suggest that artemisinin may target and 
depolarize the mitochondrial membrane potential [41, 42]. Due to these functional 
Figure 1. 
Timeline for the introduction of antimalarial drugs and emergence of resistance. Image illustrates the 
approximate timeline for the discovery of antimalarial drugs and evolution of resistance. In vitro and  
in vivo (huRBCs-reconstituted human blood chimeric/humanized mice) induction of artsunare resistance in 
laboratory strains of P. falciparum to confirm the emergence of resistance. CQ-R, chloroquine resistance; ART-
R, artemisinin resistance; Q-R, quinine resistance; MF-R, mefloquine resistance.
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attributes, artemisinin eliminates the asexual blood stage and early sexual game-
tocyte forms of P. falciparum parasites at low concentrations (nM) regardless of its 
short half-life (<1 h). To overcome the half-life issue, artemisinin and its derivatives 
(artemether, artesunate, and dihydroartemisinin; DHA) are used in combination 
with a drug of longer half-life. In Southeast Asia (SE), primary artemisinin deriva-
tive combinations used are artesunate with mefloquine and DHA with piperaquine, 
whereas in Africa artemether with lumefantrine and artesunate and amodiaquine. 
In the late 2000s, emerging artemisinin resistance was noticed in SE Asia [5, 32] 
and the most problematic situation currently is the rapid increase in failure rates of 
DHA used in combination with piperaquine. Later have been the first-line treat-
ment and the preferred ACT in most of the SE Asia [43, 44]. Artemisinin resistance 
enchants potential pressure on partner drugs to work quickly and effectively in case 
of efficacy failure of artemisinin. P. falciparum Kelch 13 (Pf-Kelch13) (located on 
chromosome 13) is shown to be primarily responsible for artemisinin resistance. 
Kelch13 protein is involved in intraerythrocytic parasite development and many 
other cellular processes including hemoglobin endocytosis responsible for parasite 
growth and antimalarial activity of artemisinin. K13 mutations in parasites mediate 
artemisinin resistance through the reduced killing potential of artemisinin drugs. 
Moreover, mutations in K13 drive the enhanced removal of damaged proteins by the 
parasite [45].
Triple artemisinin-based combination therapies (TACTs) and mass drug 
administration (MDA) are proposed to combat artemisinin resistance [46, 47]. 
Combining more than two drugs with different modes of action prevents the 
chances of multidrug resistance and its spread. MDA targets the asymptomatic 
malaria receptacles that may serve as hotbeds for the transmission and perse-
verance of resistant parasites. TACT efficacy is currently in the second phase; 
with underway Tracking Resistance to Artemisinin Collaboration II (TRAC II) 
multiple-site study. DHA, piperaquine and mefloquine, and artemether and 
lumefantrine along with amodiaquine combinations have shown promising results 
and might help to defer the evolution of artemisinin resistance. Moreover, TACTs 
might reinstate the artemisinin sensitivity in the areas prevalent for artemisinin 
resistance [48].
2.1  Experimental induction of artesunate resistance in vitro and in vivo (human 
RBCs-reconstituted NSG mice [humanized mice])
Various studies have been performed to understand artemisinin (ACT) resis-
tance being evolved in laboratory strains of P. falciparum in vitro and in human 
blood chimeric mice. Human studies suggest single-dose artemisinin-induced dor-
mant parasites in P. falciparum 3D7 or K13-infected strains of P. falciparum-infected 
patients. These parasites are most likely a reservoir for recrudescent infection 
following artemisinin mono- and combination therapy (ACT). Artemisinin-
resistant P. falciparum may be experimentally selected following different regimens 
in vitro. The selected resistant parasites could employ different mechanism(s) 
of action to escape drug pressure for extended survival. Witkowski et al. [49] 
submitted laboratory P. falciparum (F32-Tanzania) to artemisinin pressure for 
over 3 years/100 cycles to select artemisinin-resistant parasites. These artemisinin-
resistant parasite could survive up to 7000× of the initial IC50 of artemisinin 
(~10 nM) with unaltered chemosensitivity. Further, under high artemisinin 
pressure, parasites were arrested at the ring stage and re-gained their sensitive 
phenotype when drug pressure was removed. This unstable resistance phenotype 
questions the experimental generation of resistant phenotype [49]. Chavchich et al. 
[50] findings directly associated the development of resistance against artemisinin 
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derivatives in P. falciparum strains (W2 and TM91C235) with the pfmdr1 gene and 
protein expression. However, there were no changes seen in these markers when 
D6 parasites were submitted to a similar drug pressure [50]. These findings were 
attested by Tucker et al. [51]. After continuous exposure of DHA for 1–2 months 
(320 nM maximum), Cui et al. were able to generate DHA-resistant P. falciparum 
strains 7G8, Dd2, HB3, and D10 but 3D7. DHA resistance was not seen limited to 
the ring stage but also occurred in trophozoites and schizonts like artemisinin 
[52]. Rocamora et al. [53] generated artemisinin-resistant P. falciparum parasite 
lines from 6A and 11C clones of the 3D7 strain of P. falciparum. Resistant clones 
displayed a significant decrease in artemisinin sensitivity within 1.5 months of 
selection and showed the enhanced cellular response against oxidative stress 
(antioxidant defense) and protein damage (unfolded protein response; UPR) [53]. 
Major pathways associated with UPR against artemisinin resistance are reported to 
be Plasmodium reactive oxidative stress complex (PROSC) and TCP-1 ring complex 
(TRiC) [29].
Rodrigues et al. [54] generated artesunate- and mefloquine-resistant P. chabaudi 
parasite in Balb/c mice and confirmed that resistance could be generated against 
combination drugs even when both drugs are administered simultaneously 
[54]. Maslachah et al. used P. berghei ANKA-infected Swiss mice and observed 
repeated passages of artemisinin-treated parasites in mice increased the effective 
dose of artemisinin from 50% to 90% with the reduced parasite clearance time 
and recrudescence time. Additionally, repeatedly artemisinin exposed parasites 
showed dormancy and vacuole formation [55]. Humans share >85% similarity 
with murines, but for the complexity of the cellular system and specificity of the 
human immune system, in vivo mouse models are far close to an ideal model for 
studying human malaria parasites. Rodent parasites are used as surrogates for 
human parasites, but the genetic differences between rodent and human parasites 
make it difficult to correlate with human studies. Human pathogens, which do 
not infect other animal species, require an animal model that could reconstitute 
or replicate the human immune system [56]. Fortunately, the mouse-human 
chimeric animals present a viable preclinical in vivo model to study the interac-
tion of the human immune system with infectious agents. Immunodeficient mice 
engrafted with human RBCs (humanized mice) support the development of 
asexual blood-stage infection of P. falciparum [57, 58]. Artesunate-resistant (ART-
R) P. falciparum (Uganada, Palo Alto Marburg) was experimentally selected by 
submitting discontinuous artesunate pressure on P. falciparum-infected human-
ized NOD/SCID IL-2Rγ−/− immunocompromised mice reconstituted with human 
erythrocytes (huRBC). This humanized animal model supported the incremental 
increase in artesunate dosage to select 100 times ART-R parasites (240 mg/kg) 
to that of clinical dose (2.4 mg/kg). ART-R phenotype exhibited two patterns of 
IC50 in the selected parasites in vivo. Further, the first-stage phenotype showed 
substantial resistance to artemisinin in vivo (400×) without a shift seen in IC50, 
and the second-stage resistance phenotype showed an absence of response to a 
very high artemisinin dose (3200×) with a shift in IC50 and co-resistance to qui-
nine, halofantrine, and amodiaquine. This phenotype was further demonstrated 
as having high-grade and stable artemisinin resistance phenotype. This is the first 
report of its kind [59], wherein a humanized mouse model was developed and a 
stable ART-R phenotype was achieved. Moreover, mimicking the clinical double 
doe regime (for consecutive two days and 24 h apart), 41% survival was observed 
with the highest dose of artemisinin (80 mg/kg) in contrast to 80% survival in 
the single-dose protocol (240 mg/kg) (Figure 2) [59]. There have been human-
ized mouse models to study asexual blood and liver stage infection of  
P. falciparum [57, 58, 60–62] and P. vivax [63, 64].
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3. Conclusion and future perspectives
Human malaria infection remains a biggest challenge to humanity and exten-
sive research is en route to find newer therapeutic options to treat this systemic 
infectious disease, P. falciparum. Basic research has been focused to decipher 
the mechanisms of infection of Plasmodium species and biochemical, genomics, 
proteomics, and metabolomics pathways. This information is used to advance the 
applied research wherein incessant efforts are being made to design vaccines and 
drugs against this menace. An effective vaccine development against P. falciparum 
has been a cumbersome process as it takes longer durations than drug therapies. 
A variety of drugs are developed acting against all developmental stages of dif-
ferent species. The development of drug resistance is affected by various genetic 
factors (mutations in genes involved in drug transport and metabolism) as well as 
environmental factors (drug pressure, the geographical distribution of the parasite, 
etc.). Currently, artemisinin and its derivatives are the cornerstones of effective 
malaria therapy regimens. These drugs are used in “artemisinin-based combination 
therapy” for treating malarial infections where artemisinin or its derivatives are 
given in combination with another unrelated partner drug. Despite ACTs, a parasite 
is gaining resistance against almost all drugs at a frightening pace suggesting an 
urgent need to devise novel antimalarial drug(s). Advanced techniques in genomics 
and proteomics help in developing novel drugs and drug targets. Since single-drug 
therapy may lead to problems such as ineffective parasite clearance and develop-
ment of resistance, newer drug combinations are also being developed to clear 
parasites at even lower doses.
In the end, we developed humanized mice (huRBCs-reconstituted NSG mice) 
and selected stable ART-resistant P. falciparum that showed co-resistance to amo-
diaquine, quinine, and halofantrine. If resistance to artesunate and artemisinins 
Figure 2. 
Experimental selection of artesunate-resistant P. falciparum in a huRBCs-reconstituted NSG mice (PfhuRBC-
NSG). NOD.PrkdcscidIl2rg−/− (NSG) mice non-adaptively controlled residual immune responses and 
reconstituted with human RBCs (HuRBCs) were used to study of asexual blood-stage infection of P. falciparum. 
The artesunate resistance (ART-R) was developed by the stepwise selection in experimental humanized mice 
using single/flash dose (the highest dose: 240 mg/kg) and double-dose (the highest dose: 80 mg/kg) regimens. 
The stability of the resistance (ART-R) phenotype was attested in vivo by removing ART pressure for one month 
and then submitting the parasite to ART pressure. ART-R parasites exhibited co-resistance to quinine (QN), 
amodiaquine (AQ ), and halofantrine (HF), and a combination of artesunate (AS) and AQ. These ART-R 
parasites showing cross-resistance were susceptible to chloroquine (CQ ) and mefloquine (MQ ).
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evolves at such a speed along with co-resistance to quinine and other antimalari-
als, we would be left with no satisfactory option for treating severe malaria and a 
compromised choice of treatments for uncomplicated malaria. Indeed, the current 
dependence on ARTs for both uncomplicated and severe malaria, together with a 
lack of viable therapeutic alternatives, is a compromising situation. We believe this 
may have dire consequences and would cripple efforts to achieve malaria control 
globally. Therefore, novel approaches are needed to devise newer drug and their 
targets to address this drug resistance issue.
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